Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Assets: 2014-2024

Historic Current Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $738.5 million.

  • Viridian Therapeutics, Inc.\DE's Current Assets fell 25.47% to $571.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $571.9 million, marking a year-over-year decrease of 25.47%. This contributed to the annual value of $738.5 million for FY2024, which is 51.80% up from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Current Assets is $738.5 million, which was up 51.80% from $486.5 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's 5-year Current Assets high stood at $738.5 million for FY2024, and its period low was $129.6 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $486.5 million (2023), whereas its average is $552.0 million.
  • Data for Viridian Therapeutics, Inc.\DE's Current Assets shows a peak YoY spiked of 335.83% (in 2020) over the last 5 years.
  • Viridian Therapeutics, Inc.\DE's Current Assets (Yearly) stood at $129.6 million in 2020, then spiked by 54.43% to $200.2 million in 2021, then spiked by 115.41% to $431.2 million in 2022, then increased by 12.83% to $486.5 million in 2023, then soared by 51.80% to $738.5 million in 2024.